HIF1A

Hypoxia-inducible factor 1-alpha · Q16665 · HIF1A on Sugi Atlas →

917,547 patent compounds predicted against HIF1A, 600,652 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Hydrocortisone (SCHEMBL7665)	0.91	12/20
Hydrocortisone (SCHEMBL4148)	1.00	11/20
Difluprednate (SCHEMBL4580)	1.00	11/20
Difluprednate (SCHEMBL4581)	1.00	11/20
Fluorometholone (SCHEMBL5051)	1.00	11/20
Hydrocortisone Acetate (SCHEMBL7419)	1.00	11/20
Hydrocortisone Hemisuccinate Anhydrous (SCHEMBL7664)	1.00	11/20
Hydrocortisone (SCHEMBL7420)	0.94	11/20
SCHEMBL4696	0.88	11/20
Hydrocortisone (SCHEMBL4697)	0.86	11/20
SCHEMBL7986	0.60	11/20
SCHEMBL4983	0.84	10/20
Methylprednisolone Hemisuccinate (SCHEMBL7915)	0.73	10/20
SCHEMBL7513	0.64	10/20
Beclomethasone (SCHEMBL3183)	1.00	9/20
Prednisolone (SCHEMBL3233)	1.00	9/20
Prednisolone (SCHEMBL3234)	1.00	9/20
Dexamethasone (SCHEMBL3774)	1.00	9/20
Triamcinolone Acetonide (SCHEMBL4448)	1.00	9/20
Diflorasone Diacetate (SCHEMBL4556)	1.00	9/20

Clinical trials — most relevant to HIF1A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients	PHASE4	NOT_YET_RECRUITING
MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM)	PHASE2	UNKNOWN
The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy	PHASE2	NOT_YET_RECRUITING
SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme	PHASE2	UNKNOWN
Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer	PHASE2	COMPLETED
First-line Irinotecan, Lederfolin and 5FU (FOLFIRI) and Bevacizumab in Patients With Advanced Colorectal Cancer	PHASE2	COMPLETED
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
Study of the Effects of Iron on Lung Blood Pressure at High Altitude	PHASE2	WITHDRAWN
Carnosine for Peripheral Vascular Disease	PHASE2	UNKNOWN
MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer	PHASE2	UNKNOWN
Nitroglycerin Plus Intracranial Radiotherapy for Brain Metastases in NSCLC Patients	PHASE2	COMPLETED
Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment	PHASE2	COMPLETED
A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors With Liver Metastases	PHASE1	COMPLETED
EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors	PHASE1	COMPLETED
Remote Ischemic Postconditioning Increases HIF-1α Plasma Levels and Improves Cardiac Markers After Cardiac Surgery	nan	COMPLETED
Mitochondrial Function of Immune Cells in Sepsis	nan	COMPLETED
Hypoxia Inducible Factor 1 Alpha as a Novel Biomarker in Septic Shock	nan	COMPLETED
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis	nan	UNKNOWN
Effect of Post Covid-19 Hypoxia on Placenta of Normal Pregnant Women: A Possible Role of Hypoxia Inducible Factor-1α.	nan	UNKNOWN
Hypoxia Inducible factor1-Alpha Genetic Polymorphism of Obstructive Sleep Apnea	nan	UNKNOWN
Study of the Effects of Iron Levels on the Lungs at High Altitude	nan	COMPLETED
TACE Associated to Systemic Bevacizumab for the Treatment of Refractory Liver Metastases From Colorectal Cancer	nan	UNKNOWN
Selecting Hypoxic Tumours for Treatment Modification	nan	RECRUITING
Inflammatory Breast Cancer, Tumor Markers, and Factors Associated With Angiogenesis	nan	COMPLETED
Hypoxia-induced Autophagy in the Pathogenesis of MAP	nan	UNKNOWN
Intermittent Hypoxia-hyperoxia Conditioning as a New Therapeutic Intervention to Reduce Hypertension (HyperIHHC)	nan	UNKNOWN
Expression of Angiogenic Factors in Myocardial Tissue	nan	COMPLETED
Role of HIF-1α in Skeletal Muscle Aging	nan	UNKNOWN
Genes-in-Action - Hepcidin Regulation of Iron Supplementation	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a HIF1A binder may also engage these)

Protein	Name	Similarity
Q9XTA5	—	1.000	Q9XTA5 →
Q0PGG7	—	1.000	Q0PGG7 →
Q61221	—	1.000	Q61221 →
Q309Z6	—	1.000	Q309Z6 →
O35800	—	1.000	O35800 →
Q9I8A9	—	1.000	Q9I8A9 →
Q9YIB9	—	1.000	Q9YIB9 →
P97481	—	1.000	P97481 →
Q9JHS1	—	0.999	Q9JHS1 →
Q91YA9	—	0.997	Q91YA9 →
P41846	—	0.996	P41846 →
Q6YGZ5	—	0.996	Q6YGZ5 →
O88529	—	0.996	O88529 →
EPAS1	Endothelial PAS domain-containing protein 1	0.995	landscape →
Q98SW2	—	0.995	Q98SW2 →
Q17062	—	0.995	Q17062 →
Q1LYM3	—	0.995	Q1LYM3 →
Q9BE97	—	0.994	Q9BE97 →
Q6GN21	—	0.994	Q6GN21 →
A0MLS5	—	0.994	A0MLS5 →
Q9DG12	—	0.994	Q9DG12 →
Q9WTL8	—	0.994	Q9WTL8 →
G5EGD2	—	0.993	G5EGD2 →
Q25637	—	0.993	Q25637 →
Q9XYB7	—	0.993	Q9XYB7 →
Q8R4S7	—	0.993	Q8R4S7 →
O00327	—	0.993	O00327 →
Q61324	—	0.993	Q61324 →
Q22510	—	0.992	Q22510 →
Q5R4T2	—	0.992	Q5R4T2 →